Request Demo

Last update 25 Feb 2026

Norfloxacin

Last update 25 Feb 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

1,4-Dihydro-1-ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid, 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid, NFLX

+ [28]

Target

Bacterial Top II

Action

inhibitors

Mechanism

Bacterial DNA gyrase inhibitors(Bacterial DNA gyrase inhibitors)

Therapeutic Areas

Infectious DiseasesDigestive System DisordersEye Diseases+ [2]

Active Indication

Dysentery, BacillaryGastrointestinal infectionTurista+ [12]

Inactive Indication

Cystitis

Originator Organization

KYORIN Pharmaceutical Co., Ltd.

Active Organization

Central Pharmaceutical JSC No. 3

KYORIN Pharmaceutical Co., Ltd.

Nichi-Iko Pharmaceutical Co., Ltd.

+ [1]

Inactive Organization

Merck Research Laboratories Massachusetts LLC

Eurofarma Laboratórios SA

License Organization-

Drug Highest PhaseApproved

First Approval Date

Japan (15 Feb 1984),

Infectious Diseases

Regulation-

Structure/Sequence

Molecular FormulaC16H18FN3O3

InChIKeyOGJPXUAPXNRGGI-UHFFFAOYSA-N

CAS Registry70458-96-7

Clinical Trials associated with Norfloxacin

CTR20252484

/ CompletedNot Applicable

诺氟沙星胶囊在健康参与者中空腹状态下的单中心、随机、开放、单次给药、两制剂、两周期、自身交叉的生物等效性试验

[Translation] A single-center, randomized, open-label, single-dose, two-formulation, two-period, self-crossover bioequivalence study of norfloxacin capsules in healthy participants under fasting condition

本试验旨在研究单剂量空腹口服国药集团汕头金石制药有限公司研制、生产的诺氟沙星胶囊（0.1g）的药代动力学特征，并以杏林製薬株式会社持证的诺氟沙星片（BACCIDAL®，0.1g）作为参比制剂，比较两制剂的药动学参数，以评价两制剂的人体生物等效性，并观察受试制剂和参比制剂在健康参与者中的安全性。

[Translation]

This study aims to study the pharmacokinetic characteristics of a single fasting oral dose of norfloxacin capsules (0.1 g) developed and produced by Shantou Jinshi Pharmaceutical Co., Ltd. of Sinopharm Group, and to use norfloxacin tablets (BACCIDAL®, 0.1 g) certified by Kyorin Pharmaceutical Co., Ltd. as the reference preparation. The pharmacokinetic parameters of the two preparations are compared to evaluate the human bioequivalence of the two preparations and to observe the safety of the test preparation and the reference preparation in healthy participants.

Start Date16 Jul 2025

Sponsor / Collaborator

Sinopharm Shantou Jinshi Pharmaceutical Co., Ltd.

CTR20251784

/ CompletedPhase 2

诺氟沙星胶囊随机、开放、两制剂、两周期、交叉、健康人体空腹生物等效性试验

[Translation] A randomized, open-label, two-dose, two-period, crossover, fasting bioequivalence study of norfloxacin capsules in healthy volunteers

主要目的：研究健康受试者在空腹状态下，单次口服由山东鲁抗医药集团赛特有限责任公司生产的诺氟沙星胶囊0.1g（受试制剂，规格0.1g）和杏林製薬株式会社生产的诺氟沙星片0.1g（BACCIDAL®，参比制剂，规格：0.1g）的相对生物利用度，评价两制剂的生物等效性。次要目的：通过不良事件发生率、实验室检验结果、生命体征和体格检查等的变化情况观察受试制剂和参比制剂在中国健康受试者中的安全性和耐受性。

[Translation]

Main objective: To study the relative bioavailability of a single oral dose of 0.1 g of norfloxacin capsules (test preparation, specification: 0.1 g) produced by Shandong Lukang Pharmaceutical Group Saite Co., Ltd. and 0.1 g of norfloxacin tablets (BACCIDAL®, reference preparation, specification: 0.1 g) produced by Kyorin Pharmaceutical Co., Ltd. in healthy subjects under fasting state, and to evaluate the bioequivalence of the two preparations. Secondary objective: To observe the safety and tolerability of the test and reference preparations in healthy Chinese subjects by observing the changes in the incidence of adverse events, laboratory test results, vital signs, and physical examinations.

Start Date04 Jun 2025

Sponsor / Collaborator

Shandong Lukang Pharmaceutical Group Saite Co., Ltd.

CTR20244434

/ CompletedNot Applicable

诺氟沙星胶囊（0.1g）在中国健康受试者中空腹给药条件下随机、开放、单剂量、两序列、两周期、双交叉生物等效性试验

[Translation] A randomized, open-label, single-dose, two-sequence, two-period, double-crossover bioequivalence study of norfloxacin capsules (0.1 g) in Chinese healthy volunteers under fasting conditions

按有关生物等效性试验的规定，选择杏林制药株式会社为持证商的诺氟沙星片（商品名：バクシダール®，规格：100mg）为参比制剂，对云鹏医药集团有限公司生产并提供的受试制剂诺氟沙星胶囊（规格：0.1g）进行空腹给药人体生物等效性试验，比较受试制剂中药物的吸收速度和吸收程度与参比制剂的差异是否在可接受的范围内，评估两种制剂在空腹给药条件下的生物等效性。同时观察健康受试者口服受试制剂和参比制剂后的安全性。

[Translation]

According to the relevant provisions of bioequivalence test, the norfloxacin tablets (trade name: Bakushidal®, specification: 100mg) of Kyorin Pharmaceutical Co., Ltd. were selected as the reference preparation, and the test preparation norfloxacin capsules (specification: 0.1g) produced and provided by Yunpeng Pharmaceutical Group Co., Ltd. were subjected to fasting human bioequivalence test to compare whether the absorption rate and degree of the drug in the test preparation were within the acceptable range with the reference preparation, and to evaluate the bioequivalence of the two preparations under fasting conditions. At the same time, the safety of the test preparation and the reference preparation after oral administration was observed in healthy subjects.

Start Date22 Dec 2024

Sponsor / Collaborator

Yunpeng Pharmaceutical Group Co Ltd.

100 Clinical Results associated with Norfloxacin

100 Translational Medicine associated with Norfloxacin

100 Patents (Medical) associated with Norfloxacin

12,180

Literatures (Medical) associated with Norfloxacin

01 Jun 2026·COMPUTATIONAL BIOLOGY AND CHEMISTRY

Evaluation of lawsone as a potential inhibitor of Staphylococcus aureus efflux pump mediated drugs resistance: An in-vitro and in-silico study

Article

Author: Zeyadi, Mustafa ; Ali, Ehab Mostafa Mohamed ; Hosawi, Salman Bakr ; Kouidhi, Bochra ; Zmantar, Tarek ; Kazmi, Imran ; Altayeb, Hisham N ; Omar, Abdelsattar M ; Bayar, Sihem ; Chaieb, Kamel

Staphylococcus aureus (S. aureus) is a causative agent of a wide range of infections such as staphylococcal scalded skin syndrome, toxic shock syndrome, necrotizing pneumonia, endocarditis, and osteomyelitis, posing a significant challenge in clinical management. This study explores the antibacterial potential of lawsone on S. aureus using experimental and computational methods. The minimum inhibitory concentration (MIC) of lawsone (alone and in combination with erythromycin, tetracycline, norfloxacin and ciprofloxacin) on 8 clinical multi-drug resistant S. aureus was evaluated in vitro. The ability of lawsone to modulate antibiotic susceptibility was also determined. Molecular docking was carried out to investigate the binding affinities between lawsone and five efflux pumps (EPP) (NorA, NorB, MsrA, SepA, and MefA) and a ribosomal protection protein (TetM) implicated in S. aureus drug resistance. Furthermore, molecular dynamics simulations (MDS) were performed to assess the stability of the protein-ligand complexes throughout the 100 ns simulation period. In addition, the physicochemical properties, drug-likeness, and toxicity of the lawsone were predicted. Lawsone showed synergistic effects with erythromycin, tetracycline, norfloxacin, and ciprofloxacin, as indicated by the modulation factors (MF) ranging from 2 to > 16. Notably, the strain SA383 showed MF values of > 8 for two antibiotics (ciprofloxacin and erythromycin), and > 16 for norfloxacin. Molecular docking revealed strong binding affinities between lawsone and the evaluated S. aureus drug resistant proteins. The MDS confirmed the stability of the lawsone-protein complexes over 100 ns simulation period, supporting its potential as an efflux pump inhibitor (EPI). ADMET profiling of lawsone demonstrated favorable drug-likeness, pharmacokinetics, and low toxicity. Lawsone does not inhibit major cytochrome P450 enzymes. Toxicity predictions also showed no significant risks of carcinogenicity or immunotoxicity, but potential mutagenicity and nephrotoxicity which require further study. Lawsone also exhibits no predicted activity on androgen receptors, aromatase, or GABA receptors, indicating minimal hormonal disruption. These findings highlight lawsone as a promising candidate for the development of a new EPI candidate, particularly against antibiotic-resistant S. aureus.

01 Mar 2026·Journal of Environmental Sciences

Energy recovery from corn straw-based biochar@MIL-88A(Fe)-mediated anaerobic digestion of waste activated sludge under norfloxacin: Metabolism and antibiotic resistance gene fates

Article

Author: Bai, Sai ; Qian, Jin ; Chen, Guanghao ; Wu, Lan ; Jiang, Feng ; Geng, Mengqi

Norfloxacin (NOR), a commonly detected antibiotic in waste activated sludge (WAS), remains understudied in anaerobic digestion (AD). This study investigated the effect of NOR on WAS AD, with corn straw-based biochar modified with MIL-88A(Fe) (BM) added to enhance energy recovery during digestion. Accumulated methane production was inhibited by 41.86 % in the BM-mediated digestion system under 1 mg/L NOR. Moreover, NOR induced the build-up of volatile fatty acids (VFAs), hindering methanogenic pathways subsequently. Microbial community structure was altered, with an enrichment of bacteria responsible for NOR degradation and a 13.20 % reduction in the abundance of hydrogenotrophic methanogens under antibiotic stress. Methanogenesis was inhibited with the expression of related genes and enzymes suppressed. The high enzymatic activities of cytochrome P-450 (CYP450) and acetate kinase contributed to the high NOR biodegradation efficiency (88.79 %). Twelve typical antibiotic resistant genes (ARGs) types, including multidrug, aminoglycoside, macrolides (MLs), etc., were examined in the AD system. The total abundance of ARGs type and subtype increased under NOR addition, implying ARGs removal was inhibited by NOR stress. Resistance to NOR exposure was primarily associated with antibiotic efflux and alterations in antibiotic target. Horizontal gene transfer (HGT) and vertical gene transfer (VGT) were the mechanistic routes for ARG evolution, with HGT inhibited and VGT promoted following NOR addition. The dominant genus Acinetobacter was the potential host for nearly all ARGs. This study advanced understanding of the impact of NOR on WAS digestion with BM mediation, providing new insights for optimizing WAS digestion.

01 Mar 2026·BIOORGANIC CHEMISTRY

A dual-targeting antimicrobial agent: Discovery and mechanism of action of a novel 7H-Pyrrolo[3,2-f]quinazoline-1,3-diamine compound

Article

Author: Cheng, Muchun ; He, Weiqing ; Xiao, Xunli ; Li, Ke ; Song, Mingxia ; Deng, Xianqing ; Tian, Yajing ; Qin, Kunhao ; Hua, Yi ; Che, Jinman ; Jiang, Yuanying ; Fu, Qiang ; Shang, Jieya

Drug-resistant pathogens pose severe threats to public health, driving the need for new antibacterial agents. Herein, we report the design, synthesis, and biological evaluation of a series of 1,3-diamino-7H-pyrrolo[3,2-f]quinazoline derivatives (PQDs) as dual-targeting antimicrobials acting on dihydrofolate reductase (DHFR) and membrane integrity. In vitro assays showed most compounds exhibited broad-spectrum activity, with MIC values as low as 0.0625 μg/mL. Compound 4d (7-(3,4,5-trifluorobenzyl)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine) stood out, exhibiting 8-fold greater activity than the lead compound IRS-16 against all tested strains, lower toxicity to LO2 cells than 5-fluorouracil, and superior bactericidal efficacy to norfloxacin. It also displayed reduced resistance propensity (minimal MIC increase over 20 days vs. 8- to 32-fold for norfloxacin). Furthermore, compound 4d strongly inhibited ecDHFR (IC₅₀ = 0.75 nM vs. TMP's 147.1 nM), disrupted bacterial inner membranes, inhibited biofilm formation, and attenuated phage-related processes. Multi-omics analysis further confirmed that compound 4d exerts its antibacterial effects through multiple mechanisms, including synergistic DHFR inhibition, disruption of cell membrane integrity, and interference with amino acid and nucleotide metabolic pathways. In acute toxicity tests in mice, 4d showed a higher LD₅₀ (17.39 mg/kg) than IRS-16 (14.32 mg/kg), indicating better safety. These findings demonstrate that compound 4d is a promising dual-targeting antibacterial candidate for further development.

News (Medical) associated with Norfloxacin

18 Apr 2025

·pharma.economictimes.indiatimes.com

131 drugs fail CDSCO quality test, another Telma sample flagged as spurious

New Delhi: During the routine quality review check in March, a total of 131 drug samples failed to meet the quality standards, while one sample of the popular hypertension brand Telma 40 has been flagged as spurious. The monthly drug quality review alert issued by the Central Drugs Standard Control Organization (CDSCO) flagged 131 drug samples as “ Not of Standard Quality ” (NSQ) and one sample as “spurious.” Making the announcement, the Union Health Ministry informed that of the total 131 NSQ samples, 70 were identified by the Central Drugs Laboratories and the remaining 61 samples were identified by the State Drugs Testing Laboratories. In addition to this, one drug sample flagged as spurious is of popular hypertension brand “Telma 40 (Telmisartan Tab I.P. 40mg),” manufactured in February 2024 and was plucked by the regulators from West Bengal. As per the Union Health Ministry, “the spurious sample was manufactured by an unauthorized manufacturer using a brand name owned by another company, and currently the matter is under investigation.” In its remark, the apex drug regulator CDSCO has said, “the product is purported to be spurious, however, the same is subject to the outcome of investigation.” Notably, last month a separate batch of the same brand picked from West Bengal was flagged as spurious. The sample was manufactured in 2022, and the reason for the drug test failure was notified as the sample “does not conform to I.P.” Telma (Telmisartan) is an angiotensin II receptor blocker that decreases high blood pressure and has been commercially marketed in India for the past two decades. The branded generic drug is marketed by Glenmark and, as per an analysis from market research firm Pharmarack, it features among the top 20 brands in the country, with a moving annual total (MAT) value of around ₹483 crore. The NSQ drug samples flagged by the central drug laboratories in March include Pantoprazole manufactured by Kolkata-based Shangrila Industries; Albendazole tablets by Mumbai-based Digital Vision; Telmisartan tablets manufactured by Guwahati-based Swiss Garnier Life Sciences; among 67 others. While the NSQ samples identified by state drug testing laboratories include Norfloxacin tablets manufactured by Revat Laboratories; Glimepiride tablets by Kerala State Drugs and Pharmaceuticals; Sucralfate by Legend Industries; among 58 others. Under Section 17-B of the Drugs and Cosmetics Act, 1940, a drug shall be deemed spurious if it is manufactured under a name belonging to another drug; an imitation of, or a substitute for, another drug; resembles another drug in a manner likely to deceive; or if it bears upon its label or container the name of another drug, among several other provisions. For NSQ samples, the drugs that fail to meet quality standards or specifications are notified as NSQ, a term defined under Section 16(1)(a) of the Drugs and Cosmetics Act, 1940. By Online Bureau ,

09 Feb 2021

·www.globenewswire.com

Global Urinary Tract Infection Treatment Markets, 2020-2027 - Market for Penicillin and Combination Drugs Segment to Grow at Highest Rate

Dublin, Feb. 09, 2021 (GLOBE NEWSWIRE) -- The "Urinary Tract Infection Treatment Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Drug Class, Indication, Distribution Channel, and Geography" report has been added to ResearchAndMarkets.com's offering. Market for Penicillin and Combination Drugs Segment to Grow at Highest CAGR during 2020-2027. The market is expected to reach US$ 11,614.32 million by 2027 from US$ 9,106.40 million in 2019; it is estimated to grow at a CAGR of 3.2% from 2020 to 2027. The growth of the market is attributed to the growing prevalence of urinary tract infections, aging population, and emerging computing technologies for urine diagnostics. However, the lack of product awareness in emerging countries and effects associated with medication obstruct the growth of the market to a certain extent. Based on drug class, the quinolones segment held the largest share of the market in 2019; however, the penicillin and combination segment is anticipated to register the highest CAGR of 4.5% in the market during the forecast period. The future growth of the market for quinolones is mainly ascribed to the fact that it is most commonly prescribed by physicians. Ciprofloxacin, levofloxacin, and enoxacin are among the most widely used drugs for treatment. R& D in UTI treatment is expected to offer lucrative growth opportunities to the players in the global urinary tract infection treatment market. For instance, in July 2018, Lupin received approval from the US Food and Drug Administration (FDA) for generic Nitrofurantoin capsules. It is a generic version of Macrodantin offered by Alvogen Malta Operations Ltd. It is used to treat UTI caused by Staphylococcus aureus, enterococci, etc. Further, in February 2020, a France-based pharmaceutical company announced Exblifep, a combination of a novel extended-spectrum beta-lactamase inhibitor, enmetazobactam, and cefepime. i.e., the fourth-generation cephalosporin, which achieved primary endpoints in a clinical trial for complicated UTIs. Moreover, in July 2019, Healthy.io, a smartphone camera-based solutions developer, announced an agreement with Walgreens Boots Alliance, Inc. placing Healthy.io's Dip UTI test kits in boots pharmacies throughout the UK. Additionally, in May 2020, Spero Therapeutics, Inc. announced the completion of patient enrollment in its Phase 3 clinical trial, ADAPT-PO, of tebipenem HBr to treat complicated urinary tract infection (cUTI) and acute pyelonephritis (AP). In July 2019, the US FDA approved Recarbrio drug to treat cUTI and complicated intra-abdominal infection in adults. In June 2018, Achaogen, Inc. received the US FDA approval for ZEMDRI to treat cUTIs in adults. In November 2018, Allergan, announced the launch of the FDA accepted supplemental drug AVYCAZ to treat cUTIs and complicated intra-abdominal infections patients between the age group of 3 months to 18 years. Applying such strategic measures can be lucrative for the urinary tract infection treatment market during the forecast period. Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Mylan N.V., ALLERGAN, Pfizer Inc., Cipla Ltd, F. Hoffmann-La Roche Ltd, Shionogi Inc., Amway, and DuPont Nutrition & Biosciences are among the leading companies in the urinary tract infection treatment market. Key Topics Covered: 1. Introduction 2. Urinary Tract Infection Treatment Market - Key Takeaways 3. Research Methodology 3.1 Coverage 3.2 Secondary Research 3.3 Primary Research 4. Urinary Tract Infection Treatment Market - Market Landscape 4.1 Overview 4.2 PEST Analysis 4.3 Expert Opinion 5. Urinary Tract Infection Treatment Market - Key Market Dynamics 5.1 Market Drivers 5.1.1 Growing Urinary Tract Infections 5.1.2 Aging Population 5.1.3 Emerging Computing Technologies for Urine Diagnostics 5.2 Market Restraints 5.2.1 Associated Effects of Medication 5.3 Market Opportunities 5.3.1 R&D in UTI Treatment 5.4 Future Trends 5.4.1 Nutritional Supplement in UTI 6. Urinary Tract Infection Treatment Market - Global Analysis 6.1 Global Urinary Tract Infection Treatment Market Revenue Forecast and Analysis 6.2 Global Urinary Tract Infection Treatment Market, By Geography - Forecast and Analysis 6.3 Market Positioning of Key Players 7. Urinary Tract Infection Treatment Market Analysis - By Drug Class 7.1 Overview 7.2 Urinary Tract Infection Treatment Market Revenue Share, by Drug Class (2019 and 2027) 7.3 Penicillin and Combinations 7.3.1 Overview 7.3.2 Penicillin and Combinations: Urinary Tract Infection Treatment Market - Revenue and Forecast to 2027 (US$ Million) 7.3.3 Amoxicillin 7.3.4 Amoxicillin and Clavulanate Potassium 7.4 Quinolones 7.4.1 Overview 7.4.2 Quinolones: Urinary Tract Infection Treatment Market - Revenue and Forecast to 2027 (US$ Million) 7.4.3 Ciprofloxaxin 7.4.4 Levofloxaxin 7.4.5 Nalidixic Acid 7.4.6 Norfloxacin 7.4.7 Others 7.5 Cephalosporin 7.6 Aminoglycoside Antibiotics 7.7 Sulphonamides 7.8 Nutritional Supplements 7.8.1 Overview 7.8.2 Nutritional Supplements: Urinary Tract Infection Treatment Market - Revenue and Forecast to 2027 (US$ Million) 7.8.3 Cranberry Supplements 7.8.4 D-Mannose 7.8.5 Probiotics 7.8.6 Vitamin-C 8. Urinary Tract Infection Treatment Market Analysis - By Indication 8.1 Overview 8.2 Urinary Tract Infection Treatment Market Revenue Share, by Indication (2019 and 2027) 8.3 Complicated Urinary Tract Infections 8.4 Uncomplicated Urinary Tract Infections 9. Urinary Tract Infection Treatment Market Analysis - By Distribution Channel 9.1 Overview 9.2 Urinary Tract Infection Treatment Market Revenue Share, by Distribution Channel (2019 and 2027) 9.3 Hospital Pharmacies 9.4 Retail Pharmacies & Drug Stores 9.5 Gynaecology and Urology Clinics 9.6 Online Drug Stores 10. Urinary Tract Infection Treatment Market - Geographic Analysis 11. Impact of COVID-19 Pandemic on Global Urinary Tract Infection Treatment Market 12. Urinary Tract Infection Treatment Market-Industry Landscape Companies Mentioned Teva Pharmaceutical Industries Ltd Sun Pharmaceutical Industries Ltd Mylan N.V. ALLERGAN Pfizer Inc. Cipla Ltd F. Hoffmann-La Roche Ltd Shionogi Inc. Amway DuPont Nutrition & Biosciences For more information about this report visit CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Collaborate

100 Deals associated with Norfloxacin

External Link

KEGG	Wiki	ATC	Drug Bank
D00210	Norfloxacin	J01MA06 S01AE02	DB01059

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Dysentery, Bacillary	Australia	Arrotex Pharmaceuticals Pty Ltd.	13 Nov 2001
Gastrointestinal infection	Australia	Arrotex Pharmaceuticals Pty Ltd.	13 Nov 2001
Turista	Australia	Arrotex Pharmaceuticals Pty Ltd.	13 Nov 2001
Corneal Ulcer	Japan	KYORIN Pharmaceutical Co., Ltd.	24 Nov 1992
Blepharitis	Japan	Nichi-Iko Pharmaceutical Co., Ltd.	30 Jun 1989
Blepharitis	Japan	KYORIN Pharmaceutical Co., Ltd.	30 Jun 1989
Conjunctivitis	Japan	KYORIN Pharmaceutical Co., Ltd.	30 Jun 1989
Dacryocystitis	Japan	KYORIN Pharmaceutical Co., Ltd.	30 Jun 1989
Dacryocystitis	Japan	Nichi-Iko Pharmaceutical Co., Ltd.	30 Jun 1989
Hordeolum	Japan	KYORIN Pharmaceutical Co., Ltd.	30 Jun 1989
Hordeolum	Japan	Nichi-Iko Pharmaceutical Co., Ltd.	30 Jun 1989
Keratitis	Japan	Nichi-Iko Pharmaceutical Co., Ltd.	30 Jun 1989
Gonorrhea	China	Central Pharmaceutical JSC No. 3	01 Jan 1986
Prostatitis	China	Central Pharmaceutical JSC No. 3	01 Jan 1986
Salmonella Infections	China	Central Pharmaceutical JSC No. 3	01 Jan 1986
Typhoid Fever	China	Central Pharmaceutical JSC No. 3	01 Jan 1986
Urinary Tract Infections	China	Central Pharmaceutical JSC No. 3	01 Jan 1986
Infectious Diseases	Japan	KYORIN Pharmaceutical Co., Ltd.	15 Feb 1984

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cystitis	Phase 3	-	Eurofarma Laboratórios SA	01 Oct 2012

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03584724 (CTgov)	Early Phase 1	Uveitis	49	Norflo Oro (Norflo Oro)	dtfesurqhc(vdxqixvxau) = nbolkzddcd jkeqiwylsm (cvqehfzzzs, 0.75) View more	-	28 Mar 2022
				Placebo for Norflo Oro (Placebo for Norflo Oro)	dtfesurqhc(vdxqixvxau) = gedtnwlzcn jkeqiwylsm (cvqehfzzzs, 0.88) View more
NCT01037959 (Pubmed \| Gastroenterology)	Phase 3	Fibrosis	291	Norfloxacin 400 mg	ahidrvefrz(ajpdqlppoo) = vplzgtjhez dcsuydxepc (wbrzynyrgh )	-	01 Dec 2018
				Placebo	ahidrvefrz(ajpdqlppoo) = ovqqogfsgs dcsuydxepc (wbrzynyrgh )
NCT00362752 (Pubmed \| Clin Gastroenterol Hepatol)	Phase 2	Hepatopulmonary Syndrome	9	Placebo	qsvqbmkgjb(ghgktrdohv) = owqaloqpzo oufnxrfdxv (qykcvpempw )	-	01 Dec 2010
Pubmed \| Gastroenterology	Phase 3	Gastrointestinal Hemorrhage	119	Norfloxacin	nweejcglue(gvwryneztp) = vlxsveslco taxvdjrczw (amdjcuaroa ) View more	-	01 Oct 1992
				Norfloxacin (Control)	okdgtrmvrr(wsepawtjiy) = zhxrmoxnyf fkadbbuwzt (mvtwbmstrr ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis